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Abstract Phosphoinositides (PIs) play an essential role in di-
verse cellular functions. Their intracellular level is strictly regu-
lated by speci¢c PI kinases, phosphatases and phospholipases.
Recent discoveries indicate that dysfunctions in the control of
their level often lead to pathologies. This review will focus on
some human diseases whose etiologies involve PI-metabolizing
enzymes. The role of PTEN (phosphatase and tensin homolog
deleted on chromosome ten) in cancer, the impact of the Src
homology 2-containing inositol-5-phosphatase phosphatases in
acute myeloid leukemia or diabetes, the involvement of myotu-
bularin family members in genetic diseases and the implication
of OCRL1 in Lowe syndrome will be emphasized. We will also
review how some bacterial pathogens have evolved strategies to
speci¢cally manipulate the host cell PI metabolism to e⁄ciently
infect them.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Phosphoinositides (PIs) are quantitatively minor phospho-
lipids of cell membranes but their metabolism is highly active
and accurately controlled. They exert their role either as pre-
cursors of second messengers such as inositol 1,4,5-trisphos-
phate (Ins(1,4,5)P3) and diacylglycerol (DAG) or directly by
interacting with proteins and orchestrating the spatio-tempo-
ral organization of key intracellular signal transduction path-
ways [1,2]. Recent discoveries implicate PIs in a number of
physiological processes including cell proliferation, death, mo-
tility, cytoskeletal regulation, intracellular vesicle tra⁄cking
and cell metabolism [2]. Accordingly, the list of PI-metaboliz-
ing enzymes linked to the development of human diseases is
growing and becomes of great interest in biomedical research
(Table 1).
The myo-inositol head group of PIs contains ¢ve free hy-
droxyl groups but only three of them have been found to be
phosphorylated in vivo. Phosphatidylinositol (PtdIns) is the
most abundant PI in mammalian cells (approximately 10%
of total cell glycerophospholipids) and can undergo sequential
and reversible phosphorylations at position D-3, D-4 and D-5
by speci¢c kinases to generate seven di¡erent polyPIs.
PtdIns(4)P, PtdIns(4,5)P2 (each representing about 10% of
total PIs) and PtdIns are kept in a steady state in cell mem-
branes because of continuous phosphorylation/dephosphory-
lation reactions by speci¢c 4 and 5 -kinases and -phosphatases
which are not yet fully identi¢ed. This ‘canonical pathway’
produces a pool of PtdIns(4,5)P2 that can serve as a substrate
for phospholipases C (PLCs) which, upon agonist-dependent
activation, make the second messengers Ins(1,4,5)P3 and
DAG [1^3]. PtdIns, PtdIns(4)P and PtdIns(4,5)P2 can also
be phosphorylated by a family of PI 3-kinases displaying dif-
ferent substrate speci¢city [4]. As clearly shown these last
years, PI 3-kinases play a critical role in agonist-stimulated
signaling pathways [2,5]. The best-known PI 3-kinase prod-
ucts, PtdIns(3,4)P2 and PtdIns(3,4,5)P3, are rapidly and tran-
siently produced in response to agonist-mediated cell activa-
tion (classically, their level never exceed 10% of PtdIns-
(4,5)P2). PtdIns(3)P is constitutively present in small quanti-
ties and its level is generally rather stable in mammalian cells,
although minor changes are noted in some conditions.
PtdIns(5)P and PtdIns(3,5)P2 are also quantitatively minor
but their level can change upon cell activation. The D-3-phos-
phorylated PIs, and also PtdIns(4,5)P2, can speci¢cally inter-
act with protein-targeting modules. Indeed, multiple proteins
have evolved lipid-binding domains exhibiting some speci¢city
for the di¡erent classes of PIs [6]. Pleckstrin homology (PH)
domain, phox homology (PX) domain, epsin N-terminal ho-
mology (ENTH) domain, band 4.1/ezrin/radixin/moesin
(FERM) domain, and Fab1p/YOTB/Vac1p/EEA1 (FYVE)
domain are among the best PI-binding domains characterized
so far. Through these high-a⁄nity lipid^protein interactions,
newly synthesized PIs can locally recruit speci¢c signaling
proteins in response to extracellular stimuli. Thus, PI-metab-
olizing enzymes, which allow rapid and reversible formation
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of microdomains enriched in speci¢c PI species, provide a
powerful system to spatially restrict membrane signals. The
capacity of some of these enzymes to control the complex
interconversions between the di¡erent PIs, as illustrated
Fig. 1, strongly contributes to the accurate regulation and
integration of dynamic intracellular mechanisms.
In this review, we will pay attention to some human path-
ologies occurring from disruption of PI signaling. Indeed,
several PI phosphatases have recently been implicated in hu-
man diseases like cancer, myotubular myopathy, neurodegen-
erative disorder and Lowe syndrome. Moreover, we will sum-
marize how some bacterial pathogens manipulate speci¢c
steps of the host cell PI metabolism to develop their virulence.
2. Overview of PI functions
PtdIns is classically considered as precursor of other PIs
(polyPIs) through sequential phosphorylations by speci¢c ki-
nases. PtdIns(4)P is the major precursor of PtdIns(4,5)P2
through phosphorylation by PtdIns(4)P 5-kinases and can
also be phosphorylated by type II PI 3-kinases to produce
PtdIns(3,4)P2. PtdIns(4)P has been shown to bind to the cy-
toskeletal protein talin [1], suggesting that it may have a func-
tion in the cell on its own. PtdIns(5)P has long been ignored
because it is generally present in small amounts in the cell [7]
and is di⁄cult to separate from PtdIns(4)P. Its metabolic
pathway in vivo and its role are still unknown but its mass
level has been shown to increase during agonist-mediated
mammalian cell activation [8]. As described below, the bacte-
rial pathogen Shigella £exneri can induce a massive transfor-
mation of the host cell PtdIns(4,5)P2 into PtdIns(5)P during
infection [9]. Together, these recent results suggest that
PtdIns(5)P may function as an intracellular lipid messenger.
However, it is still unknown whether it can activate and/or
recruit downstream protein e¡ectors or if it is only a substrate
for a local production of quantitatively minor pools of
PtdIns(4,5)P2 or PtdIns(3,5)P2.
PtdIns(3)P is constitutively present in cells at low level and
is implicated in membrane tra⁄cking through the recruitment
of FYVE domain-containing proteins such as EEA1 (early
endosome antigen 1) [10] or PX domain-containing proteins
like the sorting nexin SNX3 [11]. In agreement, using GFP-
FYVE probes, this PI has been shown to be mainly present in
early endosomes [12]. PtdIns(3)P is phosphorylated by PIK-
fyve to produce PtdIns(3,5)P2 [2]. In yeast, PtdIns(3,5)P2 is
predicted to maintain vacuole membrane integrity, recycling
and turnover [1]. The PtdIns(3,5)P2 level is dramatically in-
creased upon hyperosmotic shock in yeast cells, whereas, in
mammalian cells, it seems to be engaged in other responses to
stress such as UV radiation [2]. Although PH or PX domains
are good candidates to interact with this PI, little is known on
the putative targets of PtdIns(3,5)P2.
PtdIns(4,5)P2 plays an essential role as substrate for the
di¡erent PI-speci¢c PLCs and is therefore the precursor of
Ins(1,4,5)P3 and DAG. It is also the substrate of the type I
PI 3-kinases producing PtdIns(3,4,5)P3. Although its global
level does not rise dramatically in stimulated cells, local in-
creases in PtdIns(4,5)P2 concentrations are likely to occur and
evidence is accumulating that this PI also acts as a signaling
molecule on its own. It can in£uence actin cytoskeleton orga-
nization through interactions with actin-binding proteins [13].
For instance, PtdIns(4,5)P2 can dissociate pro¢lin^actin com-
plexes, thereby regulating the free actin monomer concentra-
tion in the cell. Moreover, through its interaction with CapZ-
related proteins or gelsolin, PtdIns(4,5)P2 can uncap actin
¢laments, allowing elongation of pre-existing ¢laments. Inter-
estingly, Raucher et al. [14] found that PtdIns(4,5)P2 can con-
trol local adhesion energy between the plasma membrane and
the underlying cytoskeleton. Basically, when the PtdIns(4,5)P2
concentration decreases, the adhesion energy becomes smaller,
leading to the formation of membrane blebs. The interaction
of this PI with several cytoskeletal anchoring proteins such as
vinculin, talin or ERM family proteins (Ezrin, Radixin and
Moesin) could support this observation, which has broad im-
plications for the dynamics of the plasma membrane, as we
will see below.
Fig. 1. The PI metabolism and its implications in human diseases. The main pathways of PI synthesis and interconversions in mammalian cells
are shown. The enzymes in orange square boxes have been clearly associated with diseases and the corresponding diseases are indicated in or-
ange oblongs. PTEN, phosphatase and tensin homologue deleted on chromosome ten; MTMR, myotubular myopathy-related proteins; SHIP,
Src homology 2-containing inositol-5-phosphatase; OCRL, phosphatase implicated in the oculocerebrorenal syndrome of Lowe; IpgD, entry-
mediating invasin of S. £exneri.
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PtdIns(3,4,5)P3 and PtdIns(3,4)P2 are two quantitatively
minor PIs rapidly and transiently produced in response to
various agonist-mediated cell stimulations. PtdIns(3,4,5)P3 is
a critical signaling molecule able to interact with high a⁄nity
with several PH domain-containing proteins. The serine/threo-
nine kinases PDK (3-phosphoinositide-dependent kinase) and
Akt, the tyrosine kinase Btk, several exchange factors for
small G proteins, PLCQ and the adapter molecule Grb2-asso-
ciated protein 1 (Gab1) are among the best-characterized tar-
gets of PtdIns(3,4,5)P3. The local production of this PI, at the
site of PI 3-kinase stimulation, results in the recruitment of
interacting proteins, whose activation often requires a syner-
gistic e¡ect of phosphorylations or a binding with other part-
ners [2,4,5]. One of the best-characterized PI 3-kinase-depen-
dent pathways is the activation of Akt/PKB, the cellular
homolog of the retroviral oncogene v-Akt [15]. Following PI
3-kinase activation, PtdIns(3,4,5)P3 recruits Akt at the plasma
membrane by direct interaction with its PH domain. PDK-1,
which also contains a PH domain with a⁄nity for
PtdIns(3,4,5)P3, is targeted to the same area and phosphory-
lates the Thr308 of Akt. Further phosphorylation of the
Ser473 of Akt by a putative PDK-2 allows full activation of
this enzyme, which then plays an important role in the regu-
lation of many biological processes, including proliferation,
apoptosis and growth. PtdIns(3,4)P2 can be produced by hy-
drolysis of PtdIns(3,4,5)P3 by 5-phosphatases, phosphoryla-
tion of PtdIns(4)P by a type II PI 3-kinase or phosphorylation
of PtdIns(3)P by a putative 4-kinase. It is also able to bind
with high a⁄nity to the PH domain of Akt [2,15]. Moreover,
this PI can directly activate in vitro novel or atypical protein
kinases C (PKCs) such as PKCN, -O and -j [2].
3. From PI signaling to human cancer
PI 3-kinase was discovered because of its association with
the viral oncoproteins v-Src and polyomavirus middle T anti-
gen [16]. Since this initial ¢nding, many other observations
have provided compelling evidence that the type IA PI 3-ki-
nase-mediated signaling pathway is involved in mitogenesis
and transformation [2,15]. Numerous oncogenes activate
type IA PI 3-kinase and several components of the PI 3-ki-
nase/Akt pathway are dysregulated in a wide range of human
cancers, including breast, colon, ovarian, pancreatic, lym-
phoid and prostate cancers [15]. Immunohistochemical stud-
ies, using phospho-speci¢c antibodies that only recognize Akt
in an active state, have shown that Akt activity is elevated in
the various cancers listed above as well as in multiple myelo-
ma, head and neck cancers [15]. A recent analysis of the PI
3-kinase/Akt pathway in 450 tumor samples from eight di¡er-
ent tumor types has shown that Akt was activated in 55% of
these samples [17].
PTEN/MMAC1/TEP1 (for ‘phosphatase and tensin homo-
log deleted on chromosome ten’, ‘mutated in multiple ad-
vanced cancers 1’, ‘transforming growth factor L-regulated
and epithelial cell-enriched phosphatase 1’) [18] is a dual-spec-
i¢city phosphatase that recognizes both protein substrates and
Table 1
PI phosphatases implicated in human syndromes
Gene Activity Substrate speci¢city Syndromes in human Phenotype in mice References
PTEN 3-Phosphatase PtdIns(3,4)P2,
PtdIns(3,4,5)P3
Cowden disease. Increased
susceptibility to develop
various cancers. Bannayan^
Zonana syndrome
Embryo lethality of
knockout mice. Tumorigenesis
in heterozygous mice
[18^25,58]
SHIP1 5-Phosphatase PtdIns(3,4,5)P3 Inhibitory mutation
associated with a case of
acute myeloid leukemia and
chemotherapy resistance.
Potential involvement in
Paget’s disease?
Myeloproliferative phenotype
with progressive splenomegaly,
massive myeloid in¢ltration
of the lungs, shortened
lifespan of knockout mice.
Severe osteoporotic phenotype.
No tumor susceptibility
described so far
[26^28,56,59]
SHIP2 5-Phosphatase PtdIns(3,4,5)P3 Type 2 diabetes Increased sensitivity to insulin,
severe neonatal hypoglycemia,
perinatal death of knockout
mice. Increased glucose
tolerance and insulin
sensitivity in heterozygous
adult mice
[29^31]
Myotubularin
(MTM1)
3-Phosphatase PtdIns(3)P X-linked myotubular
myopathy
Generalized and progressive
myopathy starting at around
4 weeks of age, with
amyotrophy and accumulation
of central nuclei in skeletal
muscle ¢bers, leading to death
at 6^14 weeks of knockout
mice
[32^36]
MTMR2 3-Phosphatase PtdIns(3)P,
PtdIns(3,5)P2
Charcot^Marie^Tooth
disease 4B1
not described [18,37^39]
SBF2 Inactive Charcot^Marie^Tooth
disease 4B2
not described [41]
OCRL1 5-Phosphatase PtdIns(4,5)P2 Lowe syndrome Asymptomatic. Show none of
the signs of Lowe syndrome
(possible compensation by the
5-phosphatase Inpp5b in mice)
[42^46,60]
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PtdIns(3,4,5)P3. It was ¢rst identi¢ed as a tumor-suppressor
gene located on chromosome 10q23.3, a region associated
with high-grade glioblastomas, prostate and breast cancers
[19,20]. PTEN tumor-suppressor function is linked to its abil-
ity to dephosphorylate the 3P-phosphate of PtdIns(3,4,5)P3
[18,21]. Somatic mutations of PTEN are frequently found in
a variety of human cancers and germ-line mutations in PTEN
are also associated with two inherited hamartoma tumor syn-
dromes, the Cowden disease and the Bannayan^Zonana syn-
drome [18,21,22,58]. It has also been reported that Cowden
patients su¡er a high risk of breast cancer.
PTEN plays a pivotal role in downregulating PDK-1 and
Akt-dependent pathways [18,21,22]. Mutations that abolish its
catalytic activity lead to the accumulation of PtdIns(3,4,5)P3
promoting unrestrained signaling through Akt and increased
cell survival, growth and proliferation. PTEN can also a¡ect
cell cycle progression and induce a G1 arrest. Indeed, PTEN-
mediated downregulation of Akt stimulates transcription of
the cyclin-dependent kinase inhibitors (p27Kip1, p21Waf1
and p57Kip2) by Forkhead family transcription factors [23].
Interestingly, recent studies in transgenic mice have con¢rmed
the role of PTEN in the negative regulation of PI 3-kinase/
Akt-mediated tumorigenesis [24].
The negative regulation of Akt activity can also be exerted
by other inositol phosphatases either independently or in co-
operation with PTEN [25]. For instance, the Src homology
2-containing inositol-5-phosphatases, SHIP1 and SHIP2, are
important regulators of PtdIns(3,4,5)P3 level by removing its
5P-phosphate [26,27]. SHIP1 is a hematopoietic-restricted en-
zyme that plays a crucial role in the negative regulation of
immunocompetent cells [27]. Recently, a somatic mutation
within the signature motif of the phosphatase domain of the
human SHIP1 gene was reported in primary myeloid leukemia
cells [28]. This mutation, in the phosphatase active site
(V684E), generates a mutant catalytically defective in 5-phos-
phatase activity. The consequences are an enhanced Akt phos-
phorylation in response to IL-3, promotion of cell survival
under conditions of serum deprivation and resistance to
VP16-induced apoptosis. These results suggest a role of the
mutated SHIP1 gene in the development of acute leukemia
and chemotherapy resistance through deregulation of the
PtdIns(3,4,5)P3/Akt signaling pathway.
4. The PtdIns(3,4,5)P3 5-phosphatase SHIP2 in type 2 diabetes
Although SHIP2, whose expression is ubiquitous, can in-
hibit the proliferation of erythroleukemia cells in vitro [29],
this protein has rather been implicated so far in the genetic
susceptibility of type 2 diabetes. Transgenic studies in mice
support a role for SHIP2 as a critical negative regulator of
insulin signaling and sensitivity [30]. Recently, Marion et al.
[31] have reported the presence of SHIP2 gene mutations as-
sociated with type 2 diabetes in humans. Comparison of
SHIP2 cDNA from eight subjects with type 2 diabetes and
the cDNA from four control subjects shows no di¡erence in
the coding sequence but one of the diabetic subjects exhibited
a 16-bp deleted sequence in the proximal part of the SHIP2 3P
untranslated region. This mutation leads to an increased
SHIP2 expression and a decreased insulin sensitivity. These
results are in agreement with the fact that PI 3-kinase is an
important mediator of insulin actions and glucose homeosta-
sis [2,4].
5. Phosphatases of the myotubularin family in myotubular
myopathy and Charcot^Marie^Tooth disease
X-linked myotubular myopathy (XLMTM) is a severe con-
genital disorder characterized by generalized muscle weakness
and hypotonia that a¡ects one out of 50 000 newborn males.
MTM1, the gene mutated in XLMTM, was located on chro-
mosome Xq28 and cloned in 1996 [32]. More than 133 muta-
tions a¡ecting the MTM1 gene have been characterized in 328
unrelated families. MTM1 codes for a 603 amino acid ubiq-
uitously expressed protein, myotubularin, presenting the con-
served sequence of the phosphotyrosine phosphatases active
site. However, studies on its substrate speci¢city have shown
that myotubularin’s preferred substrate is PtdIns(3)P [33,34],
a PI implicated in intracellular vesicular tra⁄cking [2]. This
discovery has raised considerable interest, as myotubularin is
the ¢rst PtdIns(3)P-speci¢c phosphatase. Thus, myotubularin
may regulate the level of speci¢c PtdIns(3)P pools and relo-
cate PtdIns(3)P-binding proteins in the cell. This is supported
by the fact that overexpression of myotubularin delocalizes
EEA1, a PtdIns(3)P-binding protein, from the early endo-
somes [35]. Mice deleted for MTM1 reproduce the muscle
phenotype observed in humans [36] and provide an interesting
model to better understand the links between the PI metabo-
lism and the etiology of the disease.
Myotubularin is the founding member of a highly con-
served family of genes that comprises 13 members in eukary-
otes grouped under the name of myotubular myopathy-re-
lated proteins (MTMR) [37]. Mutations in the MTMR2
gene (65% homologous to myotubularin) are responsible for
the development of an autosomal recessive motor and sensory
demyelinating neuropathy, the Charcot^Marie^Tooth disease
type 4B1 (CMT4B1) [38]. This disease, a¡ecting the peripheral
nervous system, results from focally unfolded myelin sheaths
and Schwann cell proliferation in peripheral nerves [18]. Like
myotubularin, MTMR2 is a potent PtdIns(3)P phosphatase
but is also able to dephosphorylate PtdIns(3,5)P2 in vitro
and in yeast leading to the generation of PtdIns(5)P [39] (re-
cent results suggest that myotubularin may actually also hy-
drolyze PtdIns(3,5)P2 ; Tronche're et al., unpublished observa-
tions). Thus, MTMR2 and myotubularin could be a source of
the newly described PtdIns(5)P, whose exact function in the
cell is still unknown. A di¡erential regulation of expression of
these two proteins and the use of di¡erent pools of PtdIns(3)P
[35] could explain why these two structurally and functionally
redundant ubiquitous and cytosolic phosphatases [40] are in-
volved in di¡erent pathologies.
Recently, a new member of the myotubularin family, SBF2
(SET binding factor 2), was located to 11p15 by linkage analysis
and found to be mutated in the autosomal recessive Charcot^
Marie^Tooth disease type 4B2 (CMT4B2) with focally folded
myelin. SBF2, a member of the MTMR non-active phospha-
tase/antiphosphatase group, presents homology with MTMR2.
Interestingly, the non-active SBF2 and the phosphatase-active
MTMR2 are implicated in two subforms of CMT4B, suggest-
ing that both proteins act on the same signaling pathway [41].
One hypothesis is that the inactive SBF2 plays the role of an
adapter or regulator of the active MTMR2 form.
Characterization of the regulatory mechanisms of myotu-
bularin family members and identi¢cation of the pools of
hydrolyzed substrates should help to de¢ne their role in these
pathologies more precisely.
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6. The PtdIns(4,5)P2 5-phosphatase OCRL1 in Lowe syndrome
Lowe syndrome or oculocerebrorenal syndrome of Lowe
(OCRL) is an X-linked disorder characterized by bilateral
congenital cataracts (with defects in lens epithelial cells), renal
Fanconi syndrome (with defects in kidney epithelial cells), and
severe mental retardation. It is caused by mutations in the
OCRL1 gene, which encodes a 105 kDa PtdIns(4,5)P2 5-phos-
phatase [42,43]. This phosphatase is located in the trans-Golgi
network [42], a major sorting site involved in directing pro-
teins to the apical or basolateral domains in epithelial cells.
Cell lines from kidney proximal tubules of a patient with
Lowe syndrome accumulate PtdIns(4,5)P2 [44], consistent
with an abrogation of the phosphatase activity. It has also
been reported that OCRL-de¢cient cells secrete an abnormally
high proportion of lysosomal enzymes [45] and immuno£uo-
rescence studies show that OCRL colocalizes with a lysosomal
membrane protein in normal proximal tubule cell lines [44].
Thus, OCRL may function in regulating a speci¢c pool of
PtdIns(4,5)P2 associated with lysosomal membranes such
that a misregulation due to its loss of function would lead
to abnormal delivery of lysosomal enzymes.
Moreover, cellular abnormalities of the actin cytoskeleton
have been observed in ¢broblasts from patients with Lowe
syndrome. These cells presented a decrease in long actin stress
¢ber, a higher sensitivity to actin depolymerizing agents and
an increase in punctuate F-actin staining in their center. These
defects correlate with an abnormal distribution of gelsolin and
K-actinin, two actin-binding proteins known to be regulated
by PtdIns(4,5)P2 and Ca2þ [46]. Actin polymerization plays a
key role in the formation, maintenance, and proper function
of tight and adherent junctions, which are critical in renal
proximal tubule function, and in the di¡erentiation of lens.
Thus the OCRL protein may play a role in the regulation of
cell junctions, tra⁄cking, secretion and delivery of lysosomal
enzymes. Although the etiology of this pathology remains to
be fully understood, these data give some clues to explain how
this PI(4,5)P2 5-phosphatase de¢ciency may produce the Lowe
syndrome phenotype.
7. Roles of PIs in pathogenic bacterial invasion
The ability of an intracellular bacterium to breach the in-
testinal barrier, penetrate, survive and replicate in mammalian
cells is crucial for its pathogenicity and is dependent on multi-
ple virulence factors. The invasion process starts by the at-
tachment to the host cell membrane, followed by the internal-
ization. Some pathogens, like Listeria monocytogenes, express
surface proteins that bind to host cell receptors, leading to
membrane zippering around the bacterium and internaliza-
tion. Others, such as Shigella £exneri or Salmonella typhimu-
rium, use a type III secretion system to inject e¡ector proteins
into the host cell, leading to membrane ru¥ing and uptake
through a process resembling macropinocytosis [47]. In all
cases, the pathogens have evolved several mechanisms to hi-
jack the cellular machinery of the host cell to promote their
entry. The three following examples will emphasize how bac-
terial pathogens can speci¢cally manipulate the PI metabolism
of the host cell to develop or increase their virulence.
The Gram-positive food-borne pathogen L. monocytogenes
can cause meningitis and abortion in pregnant women. Like
many microbial pathogens, this intracellular bacterium in-
duces uptake into host cells that are normally non-phagocytic
(such as epithelial cells or hepatocytes). Entry is mediated by
the Listeria surface proteins InlA (internalin) and InlB. Mam-
malian cell lines have di¡erent susceptibilities to InlA- or
InlB-mediated uptake. The host receptor for InlA is the cal-
cium-dependent cell-surface adhesion molecule E-cadherin
[48]. InlB is a 630 amino acid protein that mediates internal-
ization into Vero, Hep-2, HeLa cells and some hepatocytes.
The receptor for InlB has been identi¢ed as the tyrosine ki-
nase Met receptor [49]. Entry of Listeria is an active process
requiring tyrosine phosphorylation and reorganization of the
actin cytoskeleton in the host cell. Interestingly, infection of
Vero cells with Listeria results in activation of the host type
IA PI 3-kinase, leading to the production of PtdIns(3,4,5)P3
and PtdIns(3,4)P2 [50]. Listeria entry into these cells is
blocked by genetic or chemical inhibition of PI 3-kinase ac-
tivity. Puri¢ed InlB is su⁄cient to induce tyrosine phosphor-
Fig. 2. Schematic representation of how bacterial pathogens disturb and use the PI metabolism to increase their virulence. A pathway implicat-
ing InlB/Met receptor/Gab1/PI 3-kinase is critical for InlB-dependent entry of L. monocytogenes in several cell lines (left panel). S. £exneri can
speci¢cally transform PtdIns(4,5)P2 into PtdIns(5)P by injecting its e¡ector IpgD into the host cell. This modi¢cation leads to a local decrease
in cytoskeleton^membrane adhesion which, in cooperation with Cdc42 and Rac, allows the formation of membrane ru¥es at the entry site of
the bacteria (right panel). Host cell is represented in green and bacteria in orange. PM, plasma membrane.
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ylation of the mammalian adapter proteins Gab1 and Cbl, the
formation of Gab1/PI 3-kinase complexes and the activation
of PI 3-kinase in the host cell [51].
Thus, the InlB/Met receptor/Gab1/PI 3-kinase pathway is
critical for InlB-dependent entry of Listeria into host cell (Fig.
2). It is still unknown how PI 3-kinase regulates Listeria up-
take but a role of its lipid products in the reorganization of
the actin cytoskeleton and/or the ¢rst phases of the phagocy-
tosis is envisaged. In J774 macrophage-like cells, InlB can
activate the small G protein Ras upstream of PI 3-kinase
and Akt in a pathway leading to nuclear factor-UB (NFUB)
activation [52]. This pathway could be involved in the host
defense or the inhibition of apoptosis during infection by Lis-
teria.
The human intestinal pathogen S. £exneri is a Gram-neg-
ative bacillus that causes bacillary dysentery in humans.
Among the proteins injected by the type III secretion system
of Shigella during invasion, four Ipas (invasion plasmid anti-
gens A^D), IpgD and its chaperone IpgE are implicated in
entry focus formation. IpgD, which has two motifs related to
the active site of mammalian inositol polyphosphate 4-phos-
phatase [53], is injected into the host cell during the ¢rst steps
of infection of epithelial cells by Shigella. It acts as an e⁄cient
PtdIns(4,5)P2 4-phosphatase and the product of host-cell
PtdIns(4,5)P2 hydrolysis, which accumulates, is PtdIns(5)P.
The transformation of PtdIns(4,5)P2 into PtdIns(5)P by IpgD
promotes a local decrease in cytoskeletal^membrane adhesion,
allowing the formation of membrane ru¥ing at the entry site
[9,54]. In agreement, expression of IpgD in ¢broblasts facili-
tates the development of Cdc42 and Rac-mediated cytoskele-
ton rearrangement, such as ¢lopodia and lamellipodia, upon
agonist stimulation. Thus, transformation of PtdIns(4,5)P2 into
PtdIns(5)P by IpgD, in cooperation with Cdc42 and Rac, two
GTPases activated and involved in the entry process of Shigel-
la, allows the formation of membrane ru¥es at the entry site
to improve the bacterial virulence (Fig. 2). The role of the
newly formed PtdIns(5)P in this process is still unknown.
Like Shigella, S. typhimurium actively invades intestinal ep-
ithelial cells by inducing membrane ru¥ing and macropinocy-
tose. Cytoskeletal and membrane remodeling required for
bacterial entry depend on the secretion into the host cell of
virulence proteins exported by the type III secretory system.
Interestingly, SigD (also known as SopB), the homolog of
IpgD in Salmonella, is also an e¡ective inositol phosphatase
[55]. SigD was recently shown to translocate into host cells via
the specialized type III secretion system and to mediate a
removal of PtdIns(4,5)P2 from the base of the ru¥e [55]. A
reduced rigidity of the membrane was observed after SigD
action. As in the case of IpgD, this was likely due to a release
of membrane^cytoskeleton interactions, thereby facilitating
plasmalemmal deformation at the entry foci. This focal dis-
appearance of PtdIns(4,5)P2 facilitates sealing of the invagi-
nations by contributing to the removal of F-actin and its
associated proteins [55]. This event appears to be required
for an e⁄cient formation of Salmonella-containing vacuoles.
Accordingly, the invasion of SigD-de¢cient Salmonella is sig-
ni¢cantly delayed.
The results obtained with the two bacterial e¡ectors, IpgD
and SigD, demonstrate that manipulation of a very speci¢c
step of the PI metabolism (i.e. local removal of PtdIns(4,5)P2)
leads to membrane/cytoskeleton remodeling, a critical feature
of the endocytic process.
8. Concluding remarks
As reviewed above, recent studies have placed several key
enzymes of the PI metabolism at the forefront of the current
biomedical research. This is particularly true for phosphatases
acting on D-3 PIs (PTEN, SHIP and MTM family members)
in which mutations or de¢ciency lead to human diseases. The
critical role of PI signaling is highlighted by bacterial patho-
gen invasion models, providing an exciting source of informa-
tion about the functions of these lipids.
Mouse knockout models have con¢rmed or pointed out the
implication of several genes encoding for enzymes of the PI
metabolism in the development of various pathologies. In
some cases, these transgenic models with dysregulated PI sig-
naling have highlighted unexpected potential implications of
PI-metabolizing enzymes in diseases. For instance, a severe
osteoporotic phenotype has recently been observed in SHIP1
knockout mice due to increased numbers of hyper-resorptive
osteoclasts that mimics the human Paget’s disease [56]. This
observation may represent an important contribution to the
understanding of this disease. Another example is provided by
Weeble mutant mice showing a mutation in the gene encoding
a type I inositol 4-phosphatase (which hydrolyzes mainly
PtdIns(3,4)P2) and suggesting a potential role of this enzyme
in cell proliferation and maturation of inhibitory synapses in
neurons [57].
An important challenge is now to better understand the
functional speci¢city within the large and complex family of
PI-metabolizing enzymes. Future work should bring infor-
mation about the expression, the localization and the regula-
tion of these enzymes. The development of new technologies
and tools for membrane and lipid signaling studies is manda-
tory to improve our understanding of the very dynamic inte-
gration and spatio-temporal regulation of di¡erent pools of
individual PIs within the cell. Elucidation of the signaling
mechanisms regulated by PI synthesis, degradation or inter-
conversion should unravel new important targets for future
drug design.
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